HIGHLIGHTS
- who: K.E. Broekman from the Department of Medical Oncology, University of Groningen, University Medical Center Groningen, GroningenPediatric Oncology, Utrecht, The Netherlands have published the article: Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores, in the Journal: (JOURNAL)
- what: The authors aimed to assess the clinical benefit of systemic therapies in recurrent ovarian cancer according to the ESMO-MCBS.
SUMMARY
Non-platinum-based chemotherapy was inferior to platinum-based chemotherapy in the MITO-8 study and platinum-based chemotherapy was therefore considered the preferred comparator treatment for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.